Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy

被引:47
|
作者
Turen, Selahattin
Ozyar, Enis [1 ]
Altundag, Kadri
Gullu, Ibrahim
Atahan, Ibtisam L.
机构
[1] Hacettepe Univ, Fac Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Fac Med, Dept Internal Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06100 Ankara, Turkey
关键词
nasopharyngeal carcinoma; chemotherapy; radiotherapy; prognostic factors; LDH;
D O I
10.1080/07357900701209103
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the treatment results and probable prognostic factors in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with neoadjuvant chemotherapy (NCT) plus conventional radiotherapy (RT) or concomitant chemoradiotherapy (CCRT) at our hospital. We retrospectively evaluated 61 patients (48 males, 13 females) with locoregionally advanced NPC treated either with 2 cycles of NCT plus RT (Group A, 37 patients) or with three cycles of NCT plus CCRT (Group B, 24 patients) between September 1995 and October 2002. According to the AJCC 1997 classification system, 19 patients had Stage III disease and 42 had Stage IV. NCT consisted of cisplatin and 5-fluorouracil. Total RT doses were ranged between 59.4-71.6 Gy (median: 66.2 Gy). Concomitant cisplatin (75 mg/ m(2)) was given on first days of Weeks 1, 4, 7 of CCRT. Patient sex, histopathologic subtype, T status, ECOG performance status, stage, serum lactate dehydrogenase (LDH) level, and cranial nerve involvement at diagnosis were comparable in the 2 groups. There were statistically significant differences between median follow-up times and N status for the 2 groups. Fifty-five (90.2 percent) patients completed all planned NCT. Univariate analysis revealed the pretreatment LDH level as the only statistically significant prognostic factor for disease-free survival (DFS) and overall survival (OS). Four-year DFS rates were 55.9 percent and 21.3 percent for patients with normal and high serum LDH levels, respectively (P = 0.04). Four-year OS rates were 68.7 percent and 28.5 percent for patients with normal and high serum LDH levels, respectively (P = 0.01). Multivariate analysis also revealed that high serum LDH level was the only independent risk factor that predicted OS. The relative risk was 2.43 (95% CI: 1.08-5.45) for patients with high serum LDH levels (P = 0.03). No independent risk factors associated with DFS were found for other prognosticators. Our study demonstrated that high serum LDH level is the only independent unfavorable risk factor for OS in patients with locoregionally advanced NPC who were treated with NCT plus RT or CCRT.
引用
收藏
页码:315 / 321
页数:7
相关论文
共 50 条
  • [31] Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: is Intergroup Study 0099 feasible in Japanese patients?
    Isobe, K
    Kawakami, H
    Uno, T
    Yasuda, S
    Aruga, T
    Ueno, N
    Kawata, T
    Ito, H
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (10) : 497 - 500
  • [32] C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy
    Zeng, Yue-Can
    Xue, Ming
    Chi, Feng
    Xu, Zhao-Guo
    Fan, Guo-Liang
    Wu, Rong
    Fan, Yu-Chen
    Zhong, Wen-Zhao
    Wang, Si-Liang
    Zhang, Xiao-Ye
    Wu, Li-Na
    Chen, Xiao-Dong
    Jin, Xue-Ying
    Duan, Qiong-Yu
    Xu, Ru
    Chen, Wei
    Qian, Hao-Chu
    Xiao, Yu-Ping
    [J]. TUMOR BIOLOGY, 2012, 33 (03) : 891 - 895
  • [33] The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy
    Guo, Shan-Shan
    Huang, Pei-Yu
    Chen, Qiu-Yan
    Liu, Huai
    Tang, Lin-Quan
    Zhang, Lu
    Liu, Li-Ting
    Cao, Ka-Jia
    Guo, Ling
    Mo, Hao-Yuan
    Guo, Xiang
    Hong, Ming-Huang
    Mai, Hai-Qiang
    [J]. RADIATION ONCOLOGY, 2014, 9 : 246
  • [34] Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
    Wang, Yueshu
    Ding, Wei
    Chen, Chuang
    Niu, Zhihao
    Pan, Ming
    Zhang, Hong
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C191 - C195
  • [35] The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy
    Shan-Shan Guo
    Pei-Yu Huang
    Qiu-Yan Chen
    Huai Liu
    Lin-Quan Tang
    Lu Zhang
    Li-Ting Liu
    Ka-Jia Cao
    Ling Guo
    Hao-Yuan Mo
    Xiang Guo
    Ming-Huang Hong
    Hai-Qiang Mai
    [J]. Radiation Oncology, 9
  • [36] Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma
    Zhang, Wendong
    Dou, Huiqin
    Lam, Chileong
    Liu, Jixi
    Zhou, Jianfeng
    Liu, Yunsheng
    Wang, Xiuwen
    [J]. TUMOR BIOLOGY, 2013, 34 (03) : 1729 - 1736
  • [37] Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
    Liu, Huai
    Qi, Bin
    Guo, Xiang
    Tang, Lin-Quan
    Chen, Qiu-Yan
    Zhang, Lu
    Guo, Ling
    Luo, Dong-Hua
    Huang, Pei-Yu
    Mo, Hao-Yuan
    Xiang, Yan-Qun
    Qiu, Fang
    Sun, Rui
    Zhang, Ying
    Chen, Ming-Yuan
    Hua, Yi-Jun
    Lv, Xing
    Wang, Lin
    Zhao, Chong
    Cao, Ka-Jia
    Qian, Chao-Nan
    Hong, Ming-Huang
    Mai, Hai-Qiang
    [J]. PLOS ONE, 2013, 8 (12):
  • [38] Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: A meta-analysis
    Zhang, Mingwei
    Wei, Shushan
    Su, Li
    Lv, Wenlong
    Hong, Jinsheng
    [J]. MEDICINE, 2016, 95 (35)
  • [39] Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy
    Zhang, Qun
    Wang, Yan
    Liao, Jun-Fang
    Ren, Yu-Feng
    Shen, Guo-Ping
    Niu, Shao-Qing
    Luo, Wei
    [J]. JOURNAL OF CANCER, 2019, 10 (17): : 3899 - 3907
  • [40] The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
    Loong, H. H. F.
    Ma, B.
    Mo, F.
    Leung, S. F.
    Hui, E. P.
    Kam, M. K.
    Chan, S. L.
    Chan, A. T. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)